The Genitourinary Cancers Program is composed of 33 investigators (29 Full and 4 Associate members) from 13 Departments. The Program consists of a group of basic and clinical investigators collectively focused upon the study and treatment of GU malignancies.
The specific aims of this Program are to: 1) Understandfundamental mechanisms that contribute to development and progression of prostate and bladder cancer; and 2) Support and advance the development of clinicians and research scientists working in a collaborative manner on GU cancers to establish novel basic, translational and clinical research programs. There are two major areas of research focus within the GU Cancer Program: prostate cancer and bladder cancer. The GU Program has developed funded research and clinical programs focused on androgen receptor (AR) signaling in prostate cancer, prostate cancer stem cells, imaging, diagnosis and focal therapy of early stage prostate cancers, as well as urothelial carcinogenesis. Utilizing these strengths, the current focus has expanded into imaging, focal therapy, molecular risk stratification, stem cell biology/etiology, and a population-based approach to racial disparity in prostate cancer. Drs. Michael Garabedian and Samir Taneja are the Co-Leaders for this Program. Total funding increased from $3,497,189 to $5,888,351 since the last competitive application. Membership has increased from 27 to 33. Publications for the period total 245, of which 26.9% are intra-programmatic, 12.2% are inter-programmatic, and 8.2% are both intra- and inter-programmatic collaborations.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Center Core Grants (P30)
Project #
Application #
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
New York University
New York
United States
Zip Code
Jin, Honglei; Yu, Yonghui; Hu, Young et al. (2015) Divergent behaviors and underlying mechanisms of cell migration and invasion in non-metastatic T24 and its metastatic derivative T24T bladder cancer cell lines. Oncotarget 6:522-36
Zhou, Sherry; Weitzman, Michael; Vilcassim, Ruzmyn et al. (2015) Air quality in New York City hookah bars. Tob Control 24:e193-8
Brocato, Jason; Costa, Max (2015) 10th NTES Conference: Nickel and arsenic compounds alter the epigenome of peripheral blood mononuclear cells. J Trace Elem Med Biol 31:209-13
Cohen, Mitchell D; Vaughan, Joshua M; Garrett, Brittany et al. (2015) Acute high-level exposure to WTC particles alters expression of genes associated with oxidative stress and immune function in the lung. J Immunotoxicol 12:140-53
Ota, Mitsuhiko; Horiguchi, Masahito; Fang, Victoria et al. (2014) Genetic suppression of inflammation blocks the tumor-promoting effects of TGF-? in gastric tissue. Cancer Res 74:2642-51
McKinney, Caleb; Zavadil, Jiri; Bianco, Christopher et al. (2014) Global reprogramming of the cellular translational landscape facilitates cytomegalovirus replication. Cell Rep 6:9-17
Vazquez-Cintron, Edwin J; Vakulenko, Maksim; Band, Philip A et al. (2014) Atoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasm. PLoS One 9:e85517
Jhaveri, Komal; Chandarlapaty, Sarat; Lake, Diana et al. (2014) A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer. Clin Breast Cancer 14:154-60
Wu, Meng; Yang, Feikun; Ren, Zhihua et al. (2014) Identification of the nuclear localization signal of SALL4B, a stem cell transcription factor. Cell Cycle 13:1456-62
Kaneko, Syuzo; Bonasio, Roberto; SaldaƱa-Meyer, Ricardo et al. (2014) Interactions between JARID2 and noncoding RNAs regulate PRC2 recruitment to chromatin. Mol Cell 53:290-300

Showing the most recent 10 out of 491 publications